Abstracts tagged "diagnosis and systemic lupus erythematosus (SLE)"

Abstract Number: 1690 • 2018 ACR/ARHP Annual Meeting
Increased Sensitivity Οf Τhe New (2017) Αnd Τhe 2012 SLICC As Compared Τo Τhe Acr 1997 Classification Criteria Ιn Early Systemic Lupus Erythematosus (SLE): The 2017 Αnd 2012 Criteria May Classify Non-Overlapping Subgroups Οf Patients
Christina Adamichou¹, Dionysios Nikolopoulos², Alessandra Bortoluzzi³, Emmanouil Papastefanakis¹, Antonis Fanouriakis², Eleni Kalogiannaki¹, Irini Gergianaki¹, Prodromos Sidiropoulos¹ and George Bertsias¹, ¹Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklion, Greece, ²4th Department of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece, ³Section of Rheumatology, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-University Hospital S. Anna, Cona Ferrara, Italy
Background/Purpose: SLE diagnosis can be challenging especially at the early stages, and existing classification criteria are biased towards classifying patients with long-standing disease. A joined…
Abstract Number: 2086 • 2016 ACR/ARHP Annual Meeting
Hexagonal Phase Phospholipid Neutralization Assay Is the Most Sensitive but Least Specific Among Nine Tests for Detecting APS in SLE or Non-SLE Patients
Katalin Banki¹, Phillip Aleksiejuk², Jessica Patel² and Andras Perl³, ¹Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ²Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, ³Department of Medicine, Upstate Medical University, Syracuse, NY
Background/Purpose: Antiphospholipid antibody syndrome (APS) is an autoimmune, hypercoagulable state which may elicit thrombosis and pregnancy loss. Although several tests exist to guide diagnosis of…
Abstract Number: 2797 • 2016 ACR/ARHP Annual Meeting
Prospective Validation of a Panel of Autoantibodies in Combination with C4d-Bound Complement Activation Products for the Differential Diagnosis of Systemic Lupus Erythematosus
Daniel J Wallace¹, Rosalind Ramsey-Goldman², Anca D. Askanase³, Susan Manzi⁴, Joseph Ahearn⁵, Richard Furie⁶, Arthur Weinstein⁷, Chaim Putterman⁸, Elena Massarotti⁹, Christopher Collins¹⁰, Kenneth Kalunian¹¹, Cristina Arriens¹², Stuart L. Silverman¹³, Smitha Reddy¹⁴, Puja Chitkara¹⁵, Claudia Ibarra¹⁶, Derren Barken¹⁷, Roberta Alexander¹⁸, John Conklin¹⁹ and Thierry Dervieux²⁰, ¹Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²FSM, Northwestern University, Chicago, IL, ³Medicine, Rheumatology, Columbia University Medical Center, New York, NY, ⁴Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ⁵Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, ⁶North Shore University Hospital, Great Neck, NY, ⁷Rheumatology Section, Washington Hospital Center, Washington, DC, ⁸Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ⁹Rheumatology, Immunology, & Allergy, Harvard Medical School, Brigham & Women's Hosp, Boston, MA, ¹⁰MedStar Washington Hospital Center, Washington, DC, ¹¹Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ¹²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³Cedars, Beverly Hills, CA, ¹⁴Arthritis Care and Research Center, Inc., Poway, CA, ¹⁵Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA, ¹⁶Clinical Laboratory, Exagen Diagnostics, Vista, CA, ¹⁷Exagen Diagnostics, Vista, CA, ¹⁸Research & Development, Exagen Diagnostics, Vista, CA, ¹⁹1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ²⁰Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose: A panel of autoantibodies in combination with C4d-bound complement activation products (CB-CAPs, EC4d and BC4d) has been established as a sensitive and specific testing…
Abstract Number: 2948 • 2015 ACR/ARHP Annual Meeting
How Do Patients with Newly Diagnosed SLE Present? a Multicenter Cohort Analysis to Inform the Development of New Classification Criteria for SLE
Marta Mosca¹, Zahi Touma², Karen H. Costenbader³, Bimba F. Hoyer⁴, Chiara Tani¹, Alexander Fine⁵, Sara Tedeschi³, Jorge Medina-Rosas⁶, Valentina Lorenzoni⁷, Gian Domenico Sebastiani⁸, Thomas Dorner⁹ and on behalf of the SLE Classification Criteria Steering committee, ¹University of Pisa, Pisa, Italy, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Charité University Medicine, Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶University of Toronto, Toronto, ON, Canada, ⁷SSSUP, Pisa, Italy, ⁸Osp. San Camillo, Roma, Italy, ⁹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine, Berlin, Germany
Background/Purpose: SLE onset may be insidious with clinically evident disease developing over years. Current SLE classification criteria may not classify patients with early SLE well.…
Abstract Number: 781 • 2015 ACR/ARHP Annual Meeting
Anti-Nucleosome Antibodies Versus Anti-DNA Antibodies in the Diagnosis and Monitoring of Activity of Systemic Lupus Erytematosus
Helena Borrell Paños¹, Javier Narváez², Jordi Bas³, Eulàlia Armengol¹, Maria Aparicio¹, Maria Pascual¹, Mercè López de Recalde¹ and Joan Miquel Nolla¹, ¹Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Immunology Department. Hospital Universitari de Bellvitge, Barcelona, Spain
Background/Purpose: Recently, the study of anti-nucleosome antibodies (ANUCs) has been suggested that they may be useful in the diagnosis of systemic lupus erythematosus (SLE) and in…
Abstract Number: 769 • 2015 ACR/ARHP Annual Meeting
Evaluation of Soluble Alpha-Klotho in Neuropsychiatric Systemic Lupus Erythematosus
Kunihiro Ichinose¹, Takeshi Ushigusa², Masataka Umeda¹, Tomohiro Koga², Atsushi Kawakami² and Shuntaro Sato³, ¹Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan
Evaluation of Soluble alpha-Klotho in Neuropsychiatric Systemic Lupus ErythematosusABSTRACTBackground/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious complication in SLE that presents a variety of…
Abstract Number: 1924 • 2014 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products Have Higher Sensitivity Than Serum C3 and C4 Levels in Systemic Lupus Erythematosus
Rosalind Ramsey-Goldman¹, Richard Furie², Chaim Putterman³, Anka Askanase⁴, Jill P. Buyon⁵, Kenneth Kalunian⁶, W. Winn Chatham⁷, E Massarotti⁸, Kyriakos A. Kirou⁹, A. Weinstein¹⁰, Puja Chitkara¹¹, Susan Manzi¹², Joe Ahearn¹³, Leilani Wolover¹⁴, John Conklin¹⁵, Tyler O'Malley¹⁴, Claudia Ibarra¹⁵, Derren Barken¹⁶ and Thierry Dervieux¹⁷, ¹FSM-300, Northwestern University, Chicago, IL, ²Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ³The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Department of Medicine Rhemuatology, Colombia University, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶UCSD School of Medicine, La Jolla, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Washington Hospital Center, Washington, DC, ¹¹Internal Medicine, Sharp Memorial Hospital, San Diego, CA, ¹²Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹³Internal Medicine, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁴Research and Development, Exagen Diagnostics, Inc., Vista, CA, ¹⁵1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ¹⁶Exagen Diagnostics, Inc., Vista, CA, ¹⁷rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Elevated levels of cell bound complement activation products (CBCAPS) have been established as valuable biomarkers in the diagnosis of Systemic Lupus Erythematosus (SLE). In…
Abstract Number: 1575 • 2013 ACR/ARHP Annual Meeting
Identification Of Novel Distinct Autoantigen Clusters Reflecting The Heterogeneity Of Systemic Lupus Erythematosus
Petra Budde¹, Angelika Lueking¹, Stefan Vordenbäumen², Heike Göhler¹, Martin Gamer¹, Klaus Marquardt¹, Anna Telaar¹, Daniel Chamrad¹, Carmen Theek¹, Peter Schulz-Knappe¹ and Matthias Schneider², ¹Protagen AG, Dortmund, Germany, ²Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
Background/Purpose: Diagnosis of systemic lupus erythematosus (SLE) is based on a combination of clinical findings and laboratory evidence such as anti-nuclear autoantibodies (ANA), anti-Smith and…